

Australia needs more testing to achieve hepatitis C elimination

AVHEC, August 2019, Sydney

Dr Nick Scott, nick.scott@burnet.edu.au

Equity Through Better Health **burnet.edu.au**

9600

Aims and purpose

Unrestricted government-subsidized direct-acting antiviral (DAA) treatment for hepatitis C means Australia is well placed to achieve the WHO hepatitis C elimination targets.

We aimed to

- 1. Assess national and sub-national progress towards these targets.
- 2. Use modelling to project the impact of continued current trends in testing and treatment.

Data

Treatment data: Pharmaceutical Benefits Scheme (PBS)

Hepatitis C prescription data, January 2013 - June 2018

Testing data: Medicare Benefits Schedule (MBS)


- Hepatitis C antibody tests cannot be identified
 - The MBS item number for hepatitis C antibody tests is shared with a number of other common blood tests
- RNA testing data were obtained by age and quarter from the internet, January 2013 June 2019
- The MBS has three categories for hepatitis C RNA testing:
 - qualitative to confirm active hepatitis C infection;
 - quantitative in preparation for treatment; or
 - qualitative to confirm treatment success.


Burnet Institute


Vf@@

Analysis methods

- An autoregressive integrated moving average (ARIMA) model was used to measure changes in testing and treatment associated with DAA availability.
- Common in econometrics for forecasting
- Can statistically identify:
 - Impact and longevity of shocks
 - Background time trends
 - Variability
- The potential epidemiological impact of continued testing and treatment trends was estimated using a mathematical model.









What if these testing/treatment trends continued?

What if treatments (in the model) were maintained?






What is happening in the model?

What about the care cascade?

If current trends in testing and treatment continue, the model projected by 2030:

Indicator	Projected 2030	2030 WHO target
Diagnosis*	81%	90%
Treatment*	70%	80%
Incidence reduction	56%	80%
People with hepatitis C	63,000	N/A


National hepatitis C care cascade



*Of people with hepatitis C in 2015

Burnet Institute

9600



What can we do about it?

Limitations

- We were unable to assess antibody testing
 - Antibody testing may have increased but simply not been successful in finding individuals who had been exposed to hepatitis C.
- RNA testing numbers do not reflect the test results
 - The pool of antibody-positive and RNA-negative individuals is increasing.
 - This makes increased testing even more important than estimated.
- There are known inconsistencies in how MBS codes are used
- Prisoners are not eligible to MBS rebates
 - We estimate that approximately an additional 5,300 tests (+10%) may have occurred during this period, which would still leave testing numbers well below what is required.*
- Differences by geography and population group

*Based on approximately 29,000 sentenced prisoners in 2018, a median sentence length of 1.9 years, a hepatitis C antibody prevalence of 31% in prisons and an estimated 50% of prisoners being hepatitis C antibody tested



9600

Take home message

- Australia's hepatitis C elimination programs need to focus on testing to maintain treatment demand.
- A 50% increase in the identification and testing of exposed patients is required by 2025 for Australia to reach the WHO hepatitis C elimination targets.

Burnet Institute

\$600

Acknowledgements

- Alex Thompson
- Alisa Pedrana
- Christian Kuschel
- Jennifer MacLachlan
- Joseph Doyle
- Margaret Hellard
- Mark Stoove
- Rachael Sacks-Davis
- Tom Tidhar

Nick Scott

Burnet institute nick.scott@burnet.edu.au +61 3 8506 2410



Of (in) (ii)
Medical Research. Practical Action.
burnet.edu.au
85 Commercial Road Melbourne, Victoria, 3004